Design Therapeutics, Inc. Payments to Acquire Investments
Design Therapeutics, Inc. (DSGN) reported Payments to Acquire Investments of $65.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireInvestments · last filed 2026-08-03
- Design Therapeutics, Inc. payments to acquire investments for the quarter ending 2026-06-30 was $12.42M, a 68.57% decline year-over-year.
- Design Therapeutics, Inc. payments to acquire investments for the quarter ending 2026-03-31 was $52.59M, a 39.24% decline year-over-year.
- Design Therapeutics, Inc. payments to acquire investments for the quarter ending 2025-12-31 was $87.62M, a 36.12% increase year-over-year.
- Design Therapeutics, Inc. payments to acquire investments for the quarter ending 2025-09-30 was $78.08M, a 17.38% increase year-over-year.
- Design Therapeutics, Inc. payments to acquire investments for fiscal 2025 was $291.78M, a 26.76% increase from fiscal 2024.
- Design Therapeutics, Inc. payments to acquire investments for fiscal 2024 was $230.18M, a 2.44% increase from fiscal 2023.
- Design Therapeutics, Inc. payments to acquire investments for fiscal 2023 was $224.70M, a 28.21% decline from fiscal 2022.
- Design Therapeutics, Inc. payments to acquire investments for fiscal 2022 was $313.00M, a 262.85% increase from fiscal 2021.
| Period end | Payments to Acquire Investments 3 month | Payments to Acquire Investments 6 month | Payments to Acquire Investments 9 month | Payments to Acquire Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $12.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $65.01M 10-Q · filed 2026-08-03 | $152.64M derived: sum of 3 quarters · filed 2026-08-03 | $230.71M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $52.59M 10-Q · filed 2026-04-28 | $140.21M derived: sum of 2 quarters · filed 2026-04-28 | $218.29M derived: sum of 3 quarters · filed 2026-04-28 | $257.82M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $87.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $165.70M derived: sum of 2 quarters · filed 2026-03-09 | $205.23M derived: sum of 3 quarters · filed 2026-08-03 | $291.78M 10-K · filed 2026-03-09 |
| 2025-09-30 | $78.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $117.61M derived: sum of 2 quarters · filed 2026-08-03 | $204.16M 10-Q · filed 2025-11-05 | $268.53M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $39.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $126.08M 10-Q · filed 2026-08-03 | $190.45M derived: sum of 3 quarters · filed 2026-08-03 | $256.96M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $86.55M 10-Q · filed 2026-04-28 | $150.92M derived: sum of 2 quarters · filed 2026-04-28 | $217.43M derived: sum of 3 quarters · filed 2026-04-28 | $271.06M derived: sum of 4 quarters · filed 2026-04-28 |
| 2024-12-31 | $64.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $130.88M derived: sum of 2 quarters · filed 2026-03-09 | $184.52M derived: sum of 3 quarters · filed 2026-03-09 | $230.18M 10-K · filed 2026-03-09 |
| 2024-09-30 | $66.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $120.14M derived: sum of 2 quarters · filed 2025-11-05 | $165.80M 10-Q · filed 2025-11-05 | $239.96M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $53.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $99.29M 10-Q · filed 2025-08-07 | $173.44M derived: sum of 3 quarters · filed 2025-08-07 | $228.01M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $45.66M 10-Q · filed 2025-05-07 | $119.81M derived: sum of 2 quarters · filed 2025-05-07 | $174.38M derived: sum of 3 quarters · filed 2025-05-07 | $236.75M derived: sum of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | $74.15M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $128.72M derived: sum of 2 quarters · filed 2025-03-10 | $191.09M derived: sum of 3 quarters · filed 2025-03-10 | $224.70M 10-K · filed 2025-03-10 |
| 2023-09-30 | $54.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $116.94M derived: sum of 2 quarters · filed 2024-11-07 | $150.55M 10-Q · filed 2024-11-07 | $211.56M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $62.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $95.98M 10-Q · filed 2024-08-05 | $156.99M derived: sum of 3 quarters · filed 2024-08-05 | $251.01M derived: sum of 4 quarters · filed 2024-08-05 |
| 2023-03-31 | $33.62M 10-Q · filed 2024-05-08 | $94.62M derived: sum of 2 quarters · filed 2024-05-08 | $188.64M derived: sum of 3 quarters · filed 2024-05-08 | |
| 2022-12-31 | $61.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $155.02M derived: sum of 2 quarters · filed 2024-03-19 | $313.00M 10-K · filed 2024-03-19 | |
| 2022-09-30 | $94.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $251.99M 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $157.98M 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $49.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $54.22M derived: sum of 2 quarters · filed 2023-03-14 | $81.15M derived: sum of 3 quarters · filed 2023-03-14 | $86.26M 10-K · filed 2023-03-14 |
| 2021-09-30 | $4.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $31.25M derived: sum of 2 quarters · filed 2022-11-03 | $36.36M 10-Q · filed 2022-11-03 | $36.36M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $26.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $32.04M 10-Q · filed 2022-08-08 | $32.04M derived: sum of 3 quarters · filed 2022-08-08 | $44.87M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $5.11M 10-Q · filed 2022-05-09 | $5.11M derived: sum of 2 quarters · filed 2022-05-09 | $17.94M derived: sum of 3 quarters · filed 2022-05-09 | $21.45M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $12.83M derived: sum of 2 quarters · filed 2022-03-10 | $16.34M derived: sum of 3 quarters · filed 2022-03-10 | $55.59M 10-K · filed 2022-03-10 |
| 2020-09-30 | $12.83M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $16.34M derived: sum of 2 quarters · filed 2021-11-09 | $55.59M 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $3.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $42.76M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $39.25M 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |